Cerevel Therapeutics to Host Virtual R&D Event on October 7
September 10, 2021 07:00 ET
|
Cerevel Therapeutics
Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of...
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
September 01, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
August 11, 2021 06:30 ET
|
Cerevel Therapeutics
Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding...
Cerevel Therapeutics Announces Redemption of Public Warrants
July 30, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience...
Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021
July 22, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
July 01, 2021 21:50 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today...
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
June 29, 2021 16:24 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today...
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
June 29, 2021 06:30 ET
|
Cerevel Therapeutics
Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo 30 mg of...
Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy
June 15, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
May 27, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it...